NO921969L - Ikke-replikerende rekombinant fremstilte retroviruspartikler brukt som antivirale midler og immunogener - Google Patents
Ikke-replikerende rekombinant fremstilte retroviruspartikler brukt som antivirale midler og immunogenerInfo
- Publication number
- NO921969L NO921969L NO92921969A NO921969A NO921969L NO 921969 L NO921969 L NO 921969L NO 92921969 A NO92921969 A NO 92921969A NO 921969 A NO921969 A NO 921969A NO 921969 L NO921969 L NO 921969L
- Authority
- NO
- Norway
- Prior art keywords
- hiv
- particles
- recombinant
- produced
- retroviral
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 6
- 241001430294 unidentified retrovirus Species 0.000 title abstract 2
- 239000003443 antiviral agent Substances 0.000 title 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract 5
- 208000031886 HIV Infections Diseases 0.000 abstract 4
- 230000001177 retroviral effect Effects 0.000 abstract 4
- 208000030507 AIDS Diseases 0.000 abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 108010008038 Synthetic Vaccines Proteins 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 230000001900 immune effect Effects 0.000 abstract 2
- 230000000877 morphologic effect Effects 0.000 abstract 2
- 229940124551 recombinant vaccine Drugs 0.000 abstract 2
- 208000003322 Coinfection Diseases 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 101710172711 Structural protein Proteins 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 108700004025 env Genes Proteins 0.000 abstract 1
- 101150030339 env gene Proteins 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000003362 replicative effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Analytical Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43920589A | 1989-11-20 | 1989-11-20 | |
| PCT/US1990/006798 WO1991007425A1 (en) | 1989-11-20 | 1990-11-20 | Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO921969D0 NO921969D0 (no) | 1992-05-19 |
| NO921969L true NO921969L (no) | 1992-06-26 |
Family
ID=23743729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO92921969A NO921969L (no) | 1989-11-20 | 1992-05-19 | Ikke-replikerende rekombinant fremstilte retroviruspartikler brukt som antivirale midler og immunogener |
Country Status (14)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990015141A2 (en) * | 1989-06-01 | 1990-12-13 | Applied Biotechnology, Inc. | Self-assembled, defective, non-self-propagating viral particles |
| US5861282A (en) * | 1989-10-16 | 1999-01-19 | Whitehead Institute For Biomedical Research | Non-infectious HIV particles and uses therefor |
| WO1991019803A1 (en) * | 1990-06-19 | 1991-12-26 | Applied Biotechnology, Incorporated | Self assembled, defective, nonself-propagating viral particles |
| DE4124817A1 (de) * | 1991-07-26 | 1993-01-28 | Basf Ag | Waessrige polymerisatdispersionen |
| EP1136562A3 (en) * | 1991-11-08 | 2003-06-25 | PHARMACIA & UPJOHN COMPANY | Feline leukemia virus vaccines |
| JPH07505412A (ja) * | 1992-04-14 | 1995-06-15 | ブリティッシュ バイオテック ファーマシューティカルズリミテッド | Ｃｔｌ応答の誘導 |
| US7001759B1 (en) | 1993-01-26 | 2006-02-21 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| PT1473369E (pt) | 1993-01-26 | 2009-03-16 | Wyeth Corp | Composições e processos para a transferência de material genético |
| DK0681483T3 (da) | 1993-01-26 | 2005-11-21 | Univ Pennsylvania | Præparater og fremgangsmåder til administration af genetisk materiale |
| GB9304239D0 (en) * | 1993-03-01 | 1993-04-21 | British Bio Technology | Viral particles |
| US5858838A (en) | 1998-02-23 | 1999-01-12 | Taiwan Semiconductor Manufacturing Company, Ltd. | Method for increasing DRAM capacitance via use of a roughened surface bottom capacitor plate |
| US5955342A (en) * | 1994-08-15 | 1999-09-21 | Connaught Laboratories Limited | Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region |
| US6291157B1 (en) | 1998-02-23 | 2001-09-18 | Connaught Laboratories Limited | Antigenically-marked non-infectious retrovirus-like particles |
| US6080408A (en) | 1994-08-22 | 2000-06-27 | Connaught Laboratories Limited | Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles |
| EP0817854A2 (en) * | 1995-03-31 | 1998-01-14 | Wolf, Hans, Prof. Dr. | Antigen presentation system based on retrovirus-like particles |
| US6013506A (en) * | 1995-06-05 | 2000-01-11 | Wardley; Richard C. | Feline leukemia virus vaccines |
| US6121021A (en) * | 1997-12-16 | 2000-09-19 | Connaught Laboratories Limited | Constitutive expression of non-infectious HIV-like particles |
| CA2358385C (en) | 1998-12-31 | 2013-08-06 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| EP1141313A2 (en) | 1998-12-31 | 2001-10-10 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
| EP1141315B1 (en) | 1998-12-31 | 2008-01-23 | Novartis Vaccines and Diagnostics, Inc. | Modified hiv env polypeptides |
| CN1311871C (zh) | 2000-03-02 | 2007-04-25 | 爱莫里大学 | Dna表达载体及其应用方法 |
| US8623379B2 (en) | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
| CA2454959C (en) * | 2001-03-08 | 2018-07-10 | Bernard Moss | Mva expressing modified hiv envelope, gag, and pol genes |
| CA2634992C (en) | 2001-07-05 | 2012-10-16 | Novartis Vaccines And Diagnostics, Inc. | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| US20030170614A1 (en) | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| KR101814857B1 (ko) | 2011-04-06 | 2018-01-04 | 바이오백심 리미티드 | 인간에서의 hiv 질환의 예방 및/또는 치료를 위한 제약 조성물 |
| EP4218805A1 (en) | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Infectious disease vaccines |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| MA55321A (fr) * | 2019-03-15 | 2022-01-19 | Modernatx Inc | Vaccins à base d'arn contre le vih |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4752565A (en) * | 1986-04-07 | 1988-06-21 | The United States Of America As Represented By The Department Of Health And Human Services | Cell line producing AIDS viral antigens without producing infectious virus particles |
| JPH02203783A (ja) * | 1989-02-02 | 1990-08-13 | Banyu Pharmaceut Co Ltd | 抗原性を有する非感染性エイズウイルス産生クローン化ヒトｔ細胞 |
| JP3140757B2 (ja) * | 1989-02-06 | 2001-03-05 | デイナ・フアーバー・キヤンサー・インステイテユート | パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用 |
| GB8923123D0 (en) * | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
| CA2067778A1 (en) * | 1989-10-16 | 1991-04-17 | The Whitehead Institute For Biomedical Research | Non-infectious hiv-1 particles and uses therefor |
-
1990
- 1990-11-20 HU HU9201659A patent/HUT60506A/hu unknown
- 1990-11-20 CA CA002068713A patent/CA2068713A1/en not_active Abandoned
- 1990-11-20 JP JP3501082A patent/JPH05503629A/ja active Pending
- 1990-11-20 WO PCT/US1990/006798 patent/WO1991007425A1/en not_active Application Discontinuation
- 1990-11-20 AU AU69055/91A patent/AU636944B2/en not_active Ceased
- 1990-11-20 KR KR1019920701189A patent/KR920703639A/ko not_active Ceased
- 1990-11-20 ES ES91900526T patent/ES2052478T1/es active Pending
- 1990-11-20 EP EP19910900526 patent/EP0502105A4/en not_active Withdrawn
- 1990-11-20 ZA ZA909302A patent/ZA909302B/xx unknown
-
1991
- 1991-01-12 TW TW080100246A patent/TW216446B/zh active
-
1992
- 1992-05-19 FI FI922277A patent/FI922277A0/fi not_active Application Discontinuation
- 1992-05-19 NO NO92921969A patent/NO921969L/no unknown
- 1992-05-19 OA OA60209A patent/OA09698A/en unknown
-
1993
- 1993-04-28 GR GR930300005T patent/GR930300005T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU9201659D0 (en) | 1992-08-28 |
| FI922277A7 (fi) | 1992-05-19 |
| KR920703639A (ko) | 1992-12-18 |
| ES2052478T1 (es) | 1994-07-16 |
| EP0502105A1 (en) | 1992-09-09 |
| EP0502105A4 (en) | 1993-02-24 |
| JPH05503629A (ja) | 1993-06-17 |
| FI922277A0 (fi) | 1992-05-19 |
| HUT60506A (en) | 1992-09-28 |
| AU6905591A (en) | 1991-06-13 |
| AU636944B2 (en) | 1993-05-13 |
| WO1991007425A1 (en) | 1991-05-30 |
| TW216446B (enrdf_load_stackoverflow) | 1993-11-21 |
| ZA909302B (en) | 1991-09-25 |
| GR930300005T1 (enrdf_load_stackoverflow) | 1993-04-28 |
| CA2068713A1 (en) | 1991-05-21 |
| OA09698A (en) | 1993-08-30 |
| NO921969D0 (no) | 1992-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO921969L (no) | Ikke-replikerende rekombinant fremstilte retroviruspartikler brukt som antivirale midler og immunogener | |
| DK33190A (da) | Hiv-3 retrovirus og anvendelse heraf | |
| Pinter et al. | Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1 | |
| Gallaher | Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus | |
| Haigwood et al. | Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies | |
| Binley et al. | Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins | |
| Myers et al. | Evolutionary potential of complex retroviruses | |
| JP3152433B2 (ja) | Ｈｉｖ感染防止用ワクチンおよび免疫療法剤 | |
| NO863803L (no) | Vaksiner og immunoanalyser for ervervet immunsviktsyndrom (aids). | |
| CN101969996A (zh) | 多价疫苗 | |
| WO1999027958A3 (en) | Hiv-1 tat, or derivatives thereof for prophylactic and therapeutic vaccination | |
| DK0495811T3 (da) | Produktion af gensplejsede vacciner mod AIDS og andre retrovirussygdomme | |
| FR2773156A1 (fr) | Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida | |
| ES2140380T3 (es) | Secuencias de adn que codifican polipeptidos gag retroviricos modificados y vacunas que las contienen o agregados de las mismas. | |
| CA2230925A1 (en) | Fusion protein delivery system and uses thereof | |
| DE60026199T2 (de) | Synthetische Gene für gagpol und deren Verwendungen | |
| De Rossi et al. | Synthetic peptides from the principal neutralizing domain of human immunodeficiency virus type 1 (HIV-1) enhance HIV-1 infection through a CD4-dependent mechanism | |
| JP2004509601A5 (enrdf_load_stackoverflow) | ||
| MY104530A (en) | Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses. | |
| AU630861B2 (en) | Recombinant hiv-2 polypeptides | |
| SE8701628D0 (sv) | Medel for analys mm | |
| EP0327180A3 (en) | Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1 | |
| Ball et al. | EIAV genomic organization: further characterization by sequencing of purified glycoproteins and cDNA | |
| Soutschek et al. | Purification of a recombinantly produced transmembrane protein (gp41) of HIV I | |
| Vogt et al. | Heterologous HIV-2 challenge of rhesus monkeys immunized with recombinant vaccinia viruses and purified recombinant HIV-2 proteins |